Eloxatin
Endometrial Carcinosarcoma
ARCAGY/ GINECO GROUPPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Endometrial Carcinosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM ARCAGY/ GINECO GROUP | Phase 2/3 | B |
Niraparib ARCAGY/ GINECO GROUP | Phase 2/3 | B |
Dostarlimab ARCAGY/ GINECO GROUP | Phase 2/3 | B |
Capecitabine ARCAGY/ GINECO GROUP | Phase 2/3 | B |
Calcium folinate pentahydrate ARCAGY/ GINECO GROUP | Phase 2/3 | B |
Pasifolate Exatecan Elucida Oncology | Phase 1/2 | CCC |
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →